Short answer
Jade Biosciences, Inc. (JBIO) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$35M
- −39.2% YoY · +37.1% QoQ
- EPS (diluted)
- −$0.39
- −205.4% YoY · +48.7% QoQ
Source: XBRL data from the Jade Biosciences, Inc. (JBIO) Q3 2026 10-Q on SEC EDGAR. USD.
Jade Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales
- Net loss $35.1M vs $25.2M YoY, operating margin not applicable due to no revenue
- JADE101 R&D $12.1M vs $6.0M, strongest program; JADE201 $3.5M vs $6.7M, weakest
- Cash and investments $475.7M, operating cash use $96.6M for nine months
- June offering net proceeds $161.6M, management expects funding for at least twelve months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Jade Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.